Pharmaceuticals, Biotechnology and Life Sciences
Allergy Therapeutics has appointed Jeff Barton to the Company’s Board as a Non-Executive Director, nominated by Abbott Laboratories in replacement of Mr Jean-Yves Pavee who retires from the Board, both effective after close of business 7 February 2017.
OptiBiotix Health has been notified by from warrant holders to exercise warrants over 16,351 ordinary shares
Sanofi has reported net income of €1,6 billion for Q4 2016 which is 6% down compared to the same period last year. The full year income was €7.3 billion, 0.9% down from the last year.
Zealand Pharma has reported royalty revenue from Sanofi’s sales of Lyxumia (lixisenatide) outside the United States of €0.7 million for Q4 2016 and annual royalty revenue of €3.3 million in 2016.
Gilead Sciences has reported net income for the fourth quarter 2016 of $3.1 billion, which is $1.6 billion less compared to same period last year.
Teva ‘s chief executive officer Erez Vigodman has stepped down from its position, and the Israel’s largest drugmaker has appointed Dr. Yitzhak Peterburg, who has served as Chairman of the Teva’s Board since January 2015, as Interim President CEO.
Nanobiotix has appointmented Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer (COO).
Amryt has secured a patent in Japan for its skin disorder drug candidate Episalvan, and it is waiting to kick off the third phase clinical trial by the end of March 2017.
U.S. Food and Drug Administration (FDA) has granted a French based biopharmaceutical company Cellectis an Investigational New Drug (IND) approval to start first phase clinical trial with UCART123 in patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Allergan said on Tuesday it wants to commit to working on preventable blindness in the USA.